A new treatment for ulcerative colitis: Intracolonic and xyloglucan application
Ulcerative colitis (UC) pathogenesis includes the altered gut microbiota, environmental factors, and human immune and genetic predisposition. Recently, its association with reduced bifidobacteria quantity in the microbiota is reported. Xyloglucan, a plant-based prebiotic oligosaccharide, causes incr...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-07-01
|
| Series: | European Journal of Inflammation |
| Online Access: | https://doi.org/10.1177/2058739220942626 |
| _version_ | 1818112790623158272 |
|---|---|
| author | Huseyin Sancar Bozkurt Banu Kara |
| author_facet | Huseyin Sancar Bozkurt Banu Kara |
| author_sort | Huseyin Sancar Bozkurt |
| collection | DOAJ |
| description | Ulcerative colitis (UC) pathogenesis includes the altered gut microbiota, environmental factors, and human immune and genetic predisposition. Recently, its association with reduced bifidobacteria quantity in the microbiota is reported. Xyloglucan, a plant-based prebiotic oligosaccharide, causes increase in bifidobacteria quantity. In this article, we share the results of our UC cases treated by intracolonic single-dose administration of Bifidobacterium animalis subsp. lactis and xyloglucan combination. Intracolonic single-dose administration of 200 billion colony-forming units (CFUs) of B. animalis subsp. lactis and 4 g of xyloglucan combination was administrated to 10 severe UC patients, who were either unresponsive or had inadequate response to treatment. All patients continued treatment after the procedure. Treatment responses were evaluated by colonoscopic, laboratory, and clinical examination after 6 weeks. Intracolonic single-dose administration of B. animalis subsp. lactis and xyloglucan was found effective in the mucosal healing and resolution of colonic symptoms in UC patients. Intracolonic administration of B. animalis subsp. lactis and xyloglucan in UC is a new single-strain and strain-specific prebiotic combination method. It is easy to apply and has no observable side effect. Its effectiveness on mucosal healing could be attributed to the enhancement of non-stimulatory status and biodiversity in colonic mucosa. Nonetheless, it is still necessary to develop diagnostic strategies to determine the patients to whom this method would be the most applicable. |
| first_indexed | 2024-12-11T03:24:32Z |
| format | Article |
| id | doaj.art-fbaf0f8cb99244e69be6bd3eb8d9dc13 |
| institution | Directory Open Access Journal |
| issn | 2058-7392 |
| language | English |
| last_indexed | 2024-12-11T03:24:32Z |
| publishDate | 2020-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | European Journal of Inflammation |
| spelling | doaj.art-fbaf0f8cb99244e69be6bd3eb8d9dc132022-12-22T01:22:33ZengSAGE PublishingEuropean Journal of Inflammation2058-73922020-07-011810.1177/2058739220942626A new treatment for ulcerative colitis: Intracolonic and xyloglucan applicationHuseyin Sancar Bozkurt0Banu Kara1Clinic of Gastroenterology, Internal Medicine Department, Faculty of Medicine, Maltepe University, Istanbul, TurkeyClinic of Gastroenterology, Adana City Research and Education Hospital, University of Health Sciences, Adana, TurkeyUlcerative colitis (UC) pathogenesis includes the altered gut microbiota, environmental factors, and human immune and genetic predisposition. Recently, its association with reduced bifidobacteria quantity in the microbiota is reported. Xyloglucan, a plant-based prebiotic oligosaccharide, causes increase in bifidobacteria quantity. In this article, we share the results of our UC cases treated by intracolonic single-dose administration of Bifidobacterium animalis subsp. lactis and xyloglucan combination. Intracolonic single-dose administration of 200 billion colony-forming units (CFUs) of B. animalis subsp. lactis and 4 g of xyloglucan combination was administrated to 10 severe UC patients, who were either unresponsive or had inadequate response to treatment. All patients continued treatment after the procedure. Treatment responses were evaluated by colonoscopic, laboratory, and clinical examination after 6 weeks. Intracolonic single-dose administration of B. animalis subsp. lactis and xyloglucan was found effective in the mucosal healing and resolution of colonic symptoms in UC patients. Intracolonic administration of B. animalis subsp. lactis and xyloglucan in UC is a new single-strain and strain-specific prebiotic combination method. It is easy to apply and has no observable side effect. Its effectiveness on mucosal healing could be attributed to the enhancement of non-stimulatory status and biodiversity in colonic mucosa. Nonetheless, it is still necessary to develop diagnostic strategies to determine the patients to whom this method would be the most applicable.https://doi.org/10.1177/2058739220942626 |
| spellingShingle | Huseyin Sancar Bozkurt Banu Kara A new treatment for ulcerative colitis: Intracolonic and xyloglucan application European Journal of Inflammation |
| title | A new treatment for ulcerative colitis: Intracolonic and xyloglucan application |
| title_full | A new treatment for ulcerative colitis: Intracolonic and xyloglucan application |
| title_fullStr | A new treatment for ulcerative colitis: Intracolonic and xyloglucan application |
| title_full_unstemmed | A new treatment for ulcerative colitis: Intracolonic and xyloglucan application |
| title_short | A new treatment for ulcerative colitis: Intracolonic and xyloglucan application |
| title_sort | new treatment for ulcerative colitis intracolonic and xyloglucan application |
| url | https://doi.org/10.1177/2058739220942626 |
| work_keys_str_mv | AT huseyinsancarbozkurt anewtreatmentforulcerativecolitisintracolonicandxyloglucanapplication AT banukara anewtreatmentforulcerativecolitisintracolonicandxyloglucanapplication AT huseyinsancarbozkurt newtreatmentforulcerativecolitisintracolonicandxyloglucanapplication AT banukara newtreatmentforulcerativecolitisintracolonicandxyloglucanapplication |